The identification of the IL6/JAK/STAT3 signaling cascade as cooperative partner in HH/GLI‐associated cancers provides a new rationale for evaluating combined HH‐IL6 targeting in BCC to improve the therapeutic efficacy of SMO inhibitor treatments. This evidence concerns the gene GLI1 and cancer.